Clearmind Medicine Announces Positive Safety Results

Clearmind Medicine Inc. has announced positive top-line safety results for its proprietary psychedelic treatment, CMND-100. The treatment successfully met its primary endpoint in a clinical trial for Alcohol Use Disorder (AUD). These findings represent a significant step forward for the company's research and development efforts in the psychedelic therapeutics space. The positive safety profile and efficacy demonstrated in the trial could pave the way for further clinical development and potential regulatory approval of CMND-100 as a novel treatment option.